Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37942
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMontalban, X.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorGobbi, C.-
dc.contributor.authorRobertson, N.-
dc.contributor.authorKlotz, L.-
dc.contributor.authorAchiron, A.-
dc.contributor.authorLee, A.-
dc.contributor.authorEichau, S.-
dc.contributor.authorVecsei, L.-
dc.contributor.authorBenzerdjeb, H.-
dc.contributor.authorRodrigues, A.-
dc.contributor.authorJurgensen, S.-
dc.contributor.authorChirieac, M.-
dc.contributor.authorComi, G.-
dc.date.accessioned2022-09-01T07:44:03Z-
dc.date.available2022-09-01T07:44:03Z-
dc.date.issued2022-
dc.date.submitted2022-08-16T11:33:57Z-
dc.identifier.citationEuropean journal of neurology (Print), 29 , p. 288-
dc.identifier.urihttp://hdl.handle.net/1942/37942-
dc.description.sponsorshipSanofi Genzyme-
dc.language.isoen-
dc.publisherWILEY-
dc.titleSafety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS)-
dc.typeJournal Contribution-
dc.identifier.spage288-
dc.identifier.volume29-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.place111 RIVER ST, HOBOKEN 07030-5774, NJ USA-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000815254001153-
local.provider.typewosris-
local.description.affiliation[Montalban, X.] Hosp Univ Vall Hebron, Dept Neurol Neuroimmunol, Ctr dEsclerosi Multiple Catalunya Cemcat, Barcelona, Spain.-
local.description.affiliation[Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium.-
local.description.affiliation[Gobbi, C.] Neuroctr Southern Switzerland, Dept Neurol, Multiple Sclerosis Ctr MSC, EOC, Lugano, Switzerland.-
local.description.affiliation[Robertson, N.] Univ Hosp Wales, Cardiff, Wales.-
local.description.affiliation[Klotz, L.] Univ Munster, Munster, Germany.-
local.description.affiliation[Achiron, A.] Chaim Sheba Med Ctr, Tel Hashomer, Israel.-
local.description.affiliation[Lee, A.] Flinders Univ S Australia, Adelaide, SA, Australia.-
local.description.affiliation[Eichau, S.] Hosp Univ Virgen Marcarena, Seville, Spain.-
local.description.affiliation[Vecsei, L.] Univ Szeged, Szeged, Hungary.-
local.description.affiliation[Benzerdjeb, H.; Rodrigues, A.] Sanofi, Chilly Mazarin, France.-
local.description.affiliation[Rodrigues, A.; Jurgensen, S.] Sanofi Cambridge, Cambridge, MA USA.-
local.description.affiliation[Comi, G.] Casa Cura Policlin, Milan, Italy.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
local.uhasselt.internationalyes-
item.contributorMontalban, X.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorGobbi, C.-
item.contributorRobertson, N.-
item.contributorKlotz, L.-
item.contributorAchiron, A.-
item.contributorLee, A.-
item.contributorEichau, S.-
item.contributorVecsei, L.-
item.contributorBenzerdjeb, H.-
item.contributorRodrigues, A.-
item.contributorJurgensen, S.-
item.contributorChirieac, M.-
item.contributorComi, G.-
item.accessRightsRestricted Access-
item.fullcitationMontalban, X.; VAN WIJMEERSCH, Bart; Gobbi, C.; Robertson, N.; Klotz, L.; Achiron, A.; Lee, A.; Eichau, S.; Vecsei, L.; Benzerdjeb, H.; Rodrigues, A.; Jurgensen, S.; Chirieac, M. & Comi, G. (2022) Safety of Alemtuzumab in Patients with Multiple Sclerosis: Interim Results of a Post-Authorization Safety Study (PASS). In: European journal of neurology (Print), 29 , p. 288.-
item.fulltextWith Fulltext-
crisitem.journal.issn1351-5101-
crisitem.journal.eissn1468-1331-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
120.pdf
  Restricted Access		Published version224.18 kBAdobe PDFView/Open    Request a copy
Show simple item record

Page view(s)

70
checked on Jul 24, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.